Soligenix (SNGX) SEC Filings: History & Chart

Soligenix, Inc.(SNGX)

Biotechnology · Princeton, NJ

$0.36-0.00 (-0.28%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Soligenix, Inc.

Soligenix, Inc., a biopharmaceutical firm in its advanced development stages, concentrates on bringing innovative products to market within the United States, specifically targeting rare illnesses. The company's operations are divided into two main divisions: Specialized BioTherapeutics and Public Health Solutions. Within the Specialized BioTherapeutics division, Soligenix is advancing SGX301 (marketed as HyBryte), a novel photodynamic treatment that has successfully completed its Phase III clinical trials for managing cutaneous T-cell lymphoma. This segment also includes SGX942, an innate defense regulator technology currently undergoing Phase III trials for various inflammatory conditions, notably oral mucositis in patients with head and neck cancer. Additionally, this division is pursuing proprietary oral formulations of beclomethasone 17,21-dipropionate designed to prevent or treat severe inflammatory gastrointestinal disorders, such as SGX203 for pediatric Crohn's disease. Another candidate, SGX302, is currently in Phase I/II clinical development for addressing mild-to-moderate psoriasis. The Public Health Solutions segment is dedicated to developing several critical assets. These include RiVax, a vaccine candidate against ricin toxin, which has successfully completed Phase Ia and Ib clinical evaluations; SGX943, a therapeutic agent in pre-clinical studies aimed at combating antibiotic-resistant and emerging infectious diseases; ThermoVax, an early-stage technology focused on enhancing vaccine thermostability; and CiVax, a pre-clinical vaccine candidate intended for COVID-19 prevention. Soligenix, Inc. was originally established as DOR BioPharma, Inc. before adopting its current name in 2009. Founded in 1987, the company maintains its corporate headquarters in Princeton, New Jersey.

Princeton, NJ

14 employees

www.soligenix.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Christopher J. Schaber

View full financials

Form	Filing Date	Accepted	Document
8-K	Sep 21, 2026	Sep 21, 2026	View filing
4	Sep 18, 2026	Sep 18, 2026	View filing
4	Sep 18, 2026	Sep 18, 2026	View filing
4	Sep 18, 2026	Sep 18, 2026	View filing
4	Sep 18, 2026	Sep 18, 2026	View filing
424B3	Aug 7, 2026	Aug 7, 2026	View filing
424B3	Aug 7, 2026	Aug 7, 2026	View filing
424B3	Aug 7, 2026	Aug 7, 2026	View filing
424B3	Aug 7, 2026	Aug 7, 2026	View filing
10-Q	Aug 7, 2026	Aug 7, 2026	View filing
ARS	Aug 3, 2026	Aug 3, 2026	View filing
DEFA14A	Aug 3, 2026	Aug 3, 2026	View filing
DEF 14A	Aug 3, 2026	Aug 3, 2026	View filing
PRER14A	Jul 23, 2026	Jul 23, 2026	View filing
PRE 14A	Jul 21, 2026	Jul 21, 2026	View filing
8-K	Jun 26, 2026	Jun 26, 2026	View filing
424B5	Jun 26, 2026	Jun 26, 2026	View filing
SC 13G	Jun 25, 2026	Jun 25, 2026	View filing
8-K	Jun 12, 2026	Jun 12, 2026	View filing
8-K	May 28, 2026	May 28, 2026	View filing
424B5	May 28, 2026	May 28, 2026	View filing
424B3	May 8, 2026	May 8, 2026	View filing
424B3	May 8, 2026	May 8, 2026	View filing
424B3	May 8, 2026	May 8, 2026	View filing
424B3	May 8, 2026	May 8, 2026	View filing
10-Q	May 8, 2026	May 8, 2026	View filing
8-K	Apr 28, 2026	Apr 28, 2026	View filing
EFFECT	Apr 2, 2026	Apr 3, 2026	View filing
EFFECT	Apr 2, 2026	Apr 3, 2026	View filing
EFFECT	Apr 2, 2026	Apr 3, 2026	View filing

SEC Filings

Recent Filings